
Anondita Medicare Limited - IPO
SMEAnondita Medicare IPO Details
Anondita Medicare IPO Subscription
Anondita Medicare IPO Application Wise Breakup
Anondita Medicare IPO Dates
- 22 Aug 2025Opening dateOPD
- 26 Aug 2025Closing dateCOD
- 28 Aug 2025Basis of AllotmentBOA
- 29 Aug 2025Initiation of RefundsIOR
- 29 Aug 2025Credit of SharesCOS
- 01 Sep 2025Listing dateLID
Anondita Medicare IPO Lot Size
Application | Lots | Shares | Amount |
---|---|---|---|
Individual Minimum | 2 | 2000 | ₹290,000 |
Individual Maximum | 2 | 2000 | ₹290,000 |
SHNI Minimum | 3 | 3000 | ₹435,000 |
SHNI Maximum | 6 | 6000 | ₹870,000 |
BHNI Minimum | 7 | 7000 | ₹1,015,000 |
Anondita Medicare IPO Reservation
Promoter Holding
Anondita Medicare IPO Valuations
Anondita Medicare Limited Financial Information
Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
Assets | 78.27 | 42.92 | 37.80 |
Total Income | 77.13 | 46.56 | 36.14 |
Profit After Tax | 16.42 | 3.84 | 0.35 |
EBITDA | 25.65 | 9.09 | 3.58 |
Net Worth | 37.87 | 10.59 | 8.69 |
Reserves and Surplus | 24.58 | 10.39 | 6.55 |
Total Borrowing | 27.39 | 24.01 | 22.66 |
Amount in ₹ Crore |
About Anondita Medicare IPO
Founded in March 2024, Anondita Medicare Limited manufactures flavored male condoms, with its flagship product branded as “COBRA.” The company produces 562 million condoms annually.
The company has a manufacturing facility situated in Noida, Uttar Pradesh.
Anondita Medicare exports its products to several international markets, including Southeast Asia, Africa, and the Middle East.
The company collaborates with global health organizations, NGOs, and governments to support family planning and public health initiatives.
Anondita Medicare has a robust distribution network that ensures the timely delivery of its products to various markets.
The company collaborates with wholesalers, retailers, and e-commerce platforms to make its products widely accessible. It also has strong ties with government health programs and institutions, playing a key role in supplying essential medical products for public health initiatives.
As on July 31, 2025, the Company had 280 employees.
Strength Of Anondita Medicare IPO
1. Production capabilities.
2. Experienced management team and a motivated and efficient work force.
3. Cordial relations with our consumers.
4. Quality assurance and control.
Risk Of Anondita Medicare IPO
1. Our Company had negative cash flows from its operating, investing and financing activities in the past and may continue to have negative cash flows in the future. Sustained negative cash flow could impact our growth and business.
2. We depend on our top 10 customers for a significant portion of our revenues. The loss of a major customer or significant reduction in demand from any of our major customers may adversely affect our business, financial condition, results of operations and prospects.
3. Our Company derives a significant portion of its revenue from government contracts and tenders for the supply of condoms under various public health initiatives. Participation in these tenders is subject to stringent regulatory compliance, quality standards, and other eligibility criteria. Any failure to meet the requirements enlisted in these tenders may result in our Company being debarred or disqualified from participating in future government tenders, which could have a material adverse effect on our business, financial condition, and results of operations.
4. Our company had obtained secured loans amounting to Rs. 2715.37 lakhs and unsecured loans amounting to Rs. 23.73 lakhs on a consolidated basis until March 31st 2025. As such any fluctuation in interest rates or change in repayment plan may adversely affect our Company's business. Moreover, unsecured loans could be recalled by our lenders at any time, which may be earlier than anticipated, affecting our repayment schedule.
5. Majority of assets, including both movable and immovable, have not yet been transferred under the name of our company.
6. Our Subsidiary, Anondita Healthcare and Rubber Products (India) Limited, have incurred losses in the past and may continue to do so in the future. We may be required to fund the operations of our Subsidiary in the future and our investments in our Subsidiary may eventually be written off, which could subject us to additional liabilities and could have an adverse effect on our Company's reputation, profitability and financial condition.
7. There is outstanding litigation pending against our company which, if determined adversely, could affect our business, results of operations and financial condition.
8. We are dependent on third parties for the distribution and marketing of our products. If we do not maintain and increase the number of our arrangements for the marketing and distribution of our products, our business, financial condition and results of operations could be adversely affected.
9. Our top three states contribute our major revenue for the Financial year ended 31st March 2025, March 31st 2024, March 31st 2023. Any loss of business from one or more of these states may adversely affect our revenues and profitability.
10. Our Registered Office and Corporate Office are shared with our promoter group companies and the same are not owned by us. Any termination of the relevant lease agreement in connection with such properties or our failure to pay annual lease rental, the same could adversely affect our operations. If we are required to vacate the same or if we are unable to renew our current leases, due to any reason whatsoever, it may adversely affect our business operations.
Objectives Anondita Medicare IPO
1. Funding capital expenditure requirements for the purchase of equipment/machineries
2. Funding the Working Capital requirement
3. Unidentified Acquisition and General Corporate Purposes
Company Contact Details
Anondita Medicare Ltd.
Flat No.704 Narmada Block,
N6, Sec-D,
Pkt-6 Vasant Kunj,
New Delhi, New Delhi, 110070
Phone: 0120-4520300
Email: info@anonditamedicare.com
Website: https://anonditamedicare.com/
Registrar Contact Details
Lead Mangers
Lead Manager Reports
Market Maker
Market Maker Reports